Get the Stockscreener App
3.47
7.59%
-0.285
Pre-market:
3.71
0.24
+6.92%
X 4 Pharmaceuticals Inc stock is traded at $3.47, with a volume of 669.90K.
It is down -7.59% in the last 24 hours and up +116.88% over the past month.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$3.755
Open:
$3.65
24h Volume:
669.90K
Relative Volume:
0.17
Market Cap:
$39.59M
Revenue:
$32.77M
Net Income/Loss:
$-101.98M
P/E Ratio:
-0.3611
EPS:
-9.6101
Net Cash Flow:
$-112.43M
1W Performance:
-24.24%
1M Performance:
+116.88%
6M Performance:
-70.72%
1Y Performance:
-83.48%
1-Day Range:
$3.2801
$3.75
1-Week Range:
$3.2801
$4.83
52-Week Range:
$1.35
$26.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
3.47 | 84.30M | 32.77M | -101.98M | -112.43M | -9.6101 |
|
VRTX
Vertex Pharmaceuticals Inc
|
401.00 | 100.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.90 | 61.55B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
447.00 | 58.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
706.41 | 43.59B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
332.04 | 33.67B | 3.81B | -644.79M | -669.77M | -6.24 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
What is the target price for X4 Pharmaceuticals Inc. stockRate Cut & AI Enhanced Market Trend Forecasts - خودرو بانک
How to recover losses in X4 Pharmaceuticals Inc. stockJuly 2025 Closing Moves & Verified Momentum Stock Ideas - Newser
Is X4 Pharmaceuticals Inc. stock ready for a breakoutJuly 2025 Technicals & Verified Momentum Stock Watchlist - Newser
X4 Pharmaceuticals Inc. stock trend forecastJuly 2025 Fed Impact & Weekly Setup with ROI Potential - Newser
How to use a screener to detect X4 Pharmaceuticals Inc. breakoutsWeekly Market Summary & Stock Market Timing Techniques - Newser
Is X4 Pharmaceuticals Inc. trending in predictive chart models2025 Price Momentum & AI Forecasted Entry and Exit Points - Newser
X4 Pharmaceuticals Inc. stock prediction for this weekStock Surge & AI Forecasted Entry/Exit Points - Newser
Identifying reversal signals in X4 Pharmaceuticals Inc.July 2025 Reactions & Low Risk Entry Point Guides - Newser
Is X4 Pharmaceuticals Inc. forming a reversal patternMarket Sentiment Summary & High Conviction Buy Zone Picks - Newser
Price momentum metrics for X4 Pharmaceuticals Inc. explainedMarket Growth Summary & Fast Gain Swing Trade Alerts - Newser
Trend analysis for X4 Pharmaceuticals Inc. this weekQuarterly Portfolio Report & AI Forecast for Swing Trade Picks - Newser
X4 Pharmaceuticals Inc. stock daily chart insightsInsider Buying & Daily Stock Trend Watchlist - Newser
Using R and stats models for X4 Pharmaceuticals Inc. forecastingProduct Launch & Fast Exit and Entry Strategy Plans - Newser
Is X4 Pharmaceuticals Inc. stock influenced by commodity prices2025 Market Overview & AI Driven Price Predictions - خودرو بانک
Is X4 Pharmaceuticals Inc. stock entering bullish territoryRecession Risk & Precise Buy Zone Tips - Newser
Multi asset correlation models including X4 Pharmaceuticals Inc.Long Setup & Real-Time Chart Breakout Alerts - Newser
What to expect from X4 Pharmaceuticals Inc. in the next 30 daysQuarterly Trade Summary & Fast Gain Swing Alerts - Newser
Real time breakdown of X4 Pharmaceuticals Inc. stock performanceMarket Risk Analysis & Free Real-Time Market Sentiment Alerts - Newser
X4 Pharmaceuticals Inc. stock trendline breakdownPortfolio Value Summary & Low Risk Entry Point Tips - Newser
Applying chart zones and confluence areas to X4 Pharmaceuticals Inc.Entry Point & AI Powered Buy/Sell Recommendations - Newser
What Fibonacci levels say about X4 Pharmaceuticals Inc. reboundJuly 2025 Update & Trade Opportunity Analysis - Newser
Will X4 Pharmaceuticals Inc. continue its uptrend2025 Top Decliners & AI Driven Stock Reports - Newser
Published on: 2025-08-31 02:01:17 - Newser
Stifel Nicolaus Issues Pessimistic Forecast for X4 Pharmaceuticals (NASDAQ:XFOR) Stock Price - Defense World
Will X4 Pharmaceuticals Inc. outperform the market2025 Year in Review & Verified Chart Pattern Signals - Newser
What are the analyst revisions for X4 Pharmaceuticals Inc.Is AMCX stock a good investment in YEAR - sundaytimes.kr
Using data tools to time your X4 Pharmaceuticals Inc. exit2025 Dividend Review & Short-Term High Return Ideas - Newser
Published on: 2025-08-30 12:12:45 - Newser
What analysts say about X4 Pharmaceuticals Inc. stock outlookWeekly Stock Recap & Weekly High Conviction Trade Ideas - Newser
Will X4 Pharmaceuticals Inc. benefit from macro trendsMarket Rally & Consistent Growth Equity Picks - Newser
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):